General
Preferred name
CEFOTETAN
Synonyms
Apacef ()
CEFOTETAN DISODIUM ()
Cefotan ()
ICI-156834 ()
ICI 156,834 ()
NSC-760045 ()
Ici-156,834 ()
Cefotetan ()
Yamatetan ()
Cefotetan Sodium ()
Cefotetan disodium salt ()
YM-09330 ()
Cefotetan (sodium salt) ()
P&D ID
PD009558
CAS
69712-56-7
74356-00-6
Tags
natural product
drug
available
Approved by
FDA
First approval
1985
Drug Status
approved
Drug indication
Bacterial infection
Antibacterial
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Cefotetan is a semi-synthetic, broad-spectrum, β-lactamase-resistant, second-generation cephalosporin antibacterial. Because of its inhibitory activity towards human aldehyde dehydrogenase, cefotetan produces an effect to ethanol similar to that produced by (Antabuse).
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
16
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
65
Molecular Weight
575.0
Hydrogen Bond Acceptors
14
Hydrogen Bond Donors
4
Rotatable Bonds
9
Ring Count
4
Aromatic Ring Count
1
cLogP
-1.4
TPSA
219.93
Fraction CSP3
0.41
Chiral centers
2.0
Largest ring
6.0
QED
0.07
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Microbiology&virology
Anti-infection
Target
Antibacterial
antibiotic
Bacterial
Indication
urinary tract infections, respiratory tract infections, skin infections, gynecologic infections, chlamydia, intra-abdominal infections, bone and joint infections, surgical prophylaxis
MOA
bacterial cell wall synthesis inhibitor
Therapeutic Class
Antibiotics
Source data
